The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The protections extend through at least 2035, with the potential for further extensions
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
